Improving immune response in oral cancer using personalized RNA vaccines
Remodeling host immunity in oral cancer with personalized RNA nanoparticle vaccines
This study is looking at a new way to help your immune system fight oral cavity squamous cell carcinoma (a tough type of cancer) by creating a personalized vaccine that uses tiny particles to deliver important information to your immune cells, with the hope of making current treatments work better for you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10875396 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune response against oral cavity squamous cell carcinoma (OCSCC), a highly aggressive cancer. It aims to develop a personalized vaccine using lipid nanoparticles that deliver tumor-derived mRNA to reprogram immune cells in the tumor microenvironment. By understanding how these myeloid cells can be influenced, the research seeks to improve the effectiveness of existing cancer treatments, particularly immune checkpoint inhibitors. Patients may benefit from a novel approach that combines vaccination with immunomodulation to better target their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with oral cavity squamous cell carcinoma who have not responded well to traditional therapies.
Not a fit: Patients with early-stage oral cancer or those whose cancer is not of the squamous cell type may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with oral cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results using similar nanoparticle vaccine approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Silver, Natalie Lea — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Silver, Natalie Lea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.